- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04786314
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome (RLS)
The Effect of Hot and Cold Water Application to Pregnant Women With Restless Legs Syndrome on Complaints and Quality of Sleep
This study was planned as a randomized controlled study to determine the effect of hot and cold water application on complaints and sleep quality in pregnant women with restless legs syndrome (RLS). Pregnant women with a total of 90 RLS, including 30 people in each group, will be included in the study. The data of this study will be collected by Personal Information Form, RLS Diagnosis Criteria Questionnaire, RLS Severity Rating Scale, Pittsburgh Sleep Quality Index, Post Application Follow-up Chart and Application Satisfaction Form.
While hot and cold water is applied in the intervention groups in the study, no application other than routine maintenance and follow-up will be done to the control group.Data analysis obtained in the research will be performed in TURCOSA statistical software (Turcosa Analytics Ltd Co, Turkey, www.turcosa.com.tr).In comparisons, a value of p <0.05 will be considered statistically significant.In order to conduct the study, the necessary Academic Committee decision, Ethics Committee approval (September 09, 2020 and number 2020/445) and institutional permission were obtained. The individuals included in the study will be informed about the purpose of the research, their verbal consent will be obtained and the participant's informed consent form will be signed.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kayseri
-
Melikgazi, Kayseri, Turkey, 38260
- Recruiting
- Erciyes University
-
Contact:
- Özlem Kaplan
- Phone Number: 05443239550
- Email: ozlemkpln-92@outlook.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Least literate
- 24-32. between the weeks of gestation
- Having a single pregnancy
- The presence of RLS is detected according to the RLS Diagnostic Criteria Questionnaire
- Having RLS due to pregnancy
- Uses Iron, Vitamin D, Magnesium and Calcium
- Pregnant women who have a severity of 11 or more according to the RLS Severity Rating Scale will be included in the study
Exclusion Criteria:
- Those who have a communication disability,
- Risky pregnancy (Preterm labor risk, Cervical insufficiency, etc.),
- Chronic disease (Diabetes, Hypertension, Thyroid, Cardiovascular disease, epilepsy, etc.),
- With maternal obesity, BMI> 30
- He has heirs in his legs,
- Pre-pregnancy sleep apnea,
- Having any psychiatric disease and using antipsychotic, antidepressant medication,
- Using antihistamine, antiepileptic, antiemetic, calcium channel blocker, dextromethorphan and decongestant type drugs,
- Using heparin,
- Pregnant women with a history of deep vein thrombosis, or atherosclerosis history or risk will not be included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Hot Water Application Group
Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
|
Pregnant women will apply hot water to their legs before going to sleep for a week.
|
|
EXPERIMENTAL: Cold Water Application Group
Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
|
Pregnant women will apply cold water to their legs before going to sleep for a week.
|
|
NO_INTERVENTION: Control Group
There will be no intervention other than routine follow-up and maintenance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RLS Severity Rating Scale
Time Frame: change from baseline score at the end of one week
|
The RLS Severity Rating Scale was developed in 2003 by the International Restless Legs Syndrome Study Group.
The scale was applied in the selection of patients and in the weekly evaluation of RLS severity.
The scale comprised ten questions; each question was scored between 0 and 4. Questions 1, 2, 4, 6, 7, and 8 were related to RLS symptoms, questions 5, 9, and 10 were related to the effect of the disease on the mental state and daily social activities of patients with RLS, and question 3 was about the diagnostic criteria of RLS.
The overall score indicated the RLS severity.
A minimum score of 0 and a maximum score of 40 could be obtained.
A score between 1 and 10 corresponded to "mild," 11-20 "moderate," 21-30 "severe," and 31-40 "very severe" RLS.
|
change from baseline score at the end of one week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pittsburgh Sleep Quality Index
Time Frame: change from baseline score at the end of one week
|
The form consists of a total of 24 questions.
Each question is scored between 0 and 3. Pittsburgh Sleep Quality Index score in the 0-21 range, with high scores indicating poor sleep quality.
If the Pittsburgh Sleep Quality Index global score is greater than 5, it indicates that the sleep quality is significantly worse.
The fact that the Pittsburgh Sleep Quality Index score is above 5 indicates that the person has serious trouble in at least two areas related to his sleep, or that he has mild or moderate difficulty in more than three areas.
|
change from baseline score at the end of one week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TDK-2020-10628
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.